[lu-177]-pnt2002,abiraterone,enzalutamide
pfizer,astellas,point biopharma,janssen
['splash', 'crpc']
point biopharma provides updated efficacy and safety data from the lead-in cohort of the phase 3 splash trial in mcrpc at esmo congress 2022 - published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: ... 
CEO Of Digital Media Online